Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a significant global health threat, largely due to its rapid evolution and high mutation rate, which often compromises the performance of existing molecular diagnostics. While conventional double-antibody sandwich immunoassays are widely used for rapid testing, their effectiveness is frequently hindered by structural steric hindrance and limited sensitivity when detecting small viral components like the nucleocapsid (N) protein.

An artificial intelligence–driven transfer learning strategy enabled the discovery of a novel indolopyridine-based small molecule (Compound 8a) that directly targets gp130, potently suppresses the JAK2/STAT3 signaling pathway, and effectively inhibits colorectal cancer growth in vitro and in vivo, offering a promising lead and a feasible computational paradigm for developing gp130‑targeted anticancer agents.

A novel network community–based computational platform, HerbSyner_Finder, efficiently identifies synergistic ingredient pairs from complex herbal medicines by integrating network proximity and Louvain community analysis. Using cough variant asthma (CVA) as a model disease, the tool prioritizes berberine-luteolin and kaempferol-quercetin as potent synergistic combinations; berberine-luteolin acts via the NLRP3/NF-κB pathway to alleviate airway inflammation, offering a universal strategy for herbal combination drug discovery.

A research team led by Professor Jianwu Dai from the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, in collaboration with Professor Rui Gu’s team from the China-Japan Union Hospital of Jilin University and Professor Yi Cui from the National Research Institute for Family Planning, has developed a novel therapeutic paradigm for spinal cord injury repair. By integrating the physical signaling regulation of traditional Chinese electroacupuncture with modern tissue engineering regenerative strategies, this study establishes a new treatment model that integrates complementary strategies from Eastern and Western medical practices.

A new study published in Microbiome Research Reports shows that patients with inflammatory bowel disease (IBD) can be stratified into distinct gut microbiome “cluster types” associated with differences in disease severity and progression risk. Rather than individual bacterial taxa, the study highlights community-level microbial structures as more robust indicators of disease heterogeneity. These microbiome-derived clusters were independent of traditional clinical classifications such as Crohn’s disease and ulcerative colitis, suggesting that gut ecosystem organization may offer complementary insights for disease assessment and future precision medicine.

Researchers at Nanjing University developed platinum(IV)-antibody conjugates that enhance tumor immunogenicity without relying on strong cancer cell killing. The targeted system delivers low-dose platinum selectively to tumors, increasing MHC-I expression and improving immune recognition while reducing systemic toxicity. In mouse models, the strategy significantly enhanced the efficacy of anti-PD-1 immunotherapy.